Johnson & Johnson

Views & Analysis

Reimagining the future of healthcare

Johnson & Johnson’s global head of external innovation, William 'Bill' Hait, describes innovation as often being “an overnight success you’ve worked on for many years”.

News

Bayer files prostate cancer drug darolutamide in Japan

Bayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the pressure on rivals Johnson & Johnson and Pfizer/Astellas.

News

Bayer/Orion showcase results from prostate cancer challenger

Bayer and development partner Orion have released detailed results from the trial that will form the backbone of its filing for their latest prostate cancer drug, as they aim to take on two

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

Janssen's esketamine depression drug set for key panel vote

Janssen’s potential depression treatment made from esketamine – a version of the substance notoriously used illegally as a party drug – is to be reviewed by advisers to the FDA at a crunch

News

Sanofi's Darzalex rival hits the mark in phase 3 trial

Johnson & Johnson’s Darzalex multiple myeloma drug has just become a blockbuster – but it could face competition from a rival from Sanofi that has just checked out in a phase 3 trial.

News

Novartis makes quality of life case for Cosentyx with new da...

There is increasing recognition that skin clearance scores may not be enough to win over patients and doctors when it comes to the highly competitive market for psoriasis drugs, even though

Reimagining the future of healthcare

Bayer files prostate cancer drug darolutamide in Japan

Bayer/Orion showcase results from prostate cancer challenger

Janssen's esketamine depression drug set for key panel vote

Sanofi's Darzalex rival hits the mark in phase 3 trial

Novartis makes quality of life case for Cosentyx with new da...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Johnson &amp; Johnson

Editor's Picks

Johnson & Johnson